CHMP anbefalede derfor tilbagekaldelse af alle markedsføringstilladelser for lægemidler indeholdende veraliprid i hele EU.
Therefore, the CHMP recommended the withdrawal of all Marketing Authorisations for medicinal products containing veralipride throughout Europe.